140 related articles for article (PubMed ID: 31217176)
1. Immune Complexes and the Risk of CVD in Type 1 Diabetes.
Lopes-Virella MF; Bebu I; Hunt KJ; Virella G; Baker NL; Braffett B; Gao X; Lachin JM;
Diabetes; 2019 Sep; 68(9):1853-1860. PubMed ID: 31217176
[TBL] [Abstract][Full Text] [Related]
2. Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Lachin J; Nathan DM; Virella G;
Diabetes; 2011 Feb; 60(2):582-9. PubMed ID: 20980456
[TBL] [Abstract][Full Text] [Related]
3. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G; Moritz T;
Atherosclerosis; 2012 Oct; 224(2):526-31. PubMed ID: 22963984
[TBL] [Abstract][Full Text] [Related]
4. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes.
Hunt KJ; Baker N; Cleary P; Backlund JY; Lyons T; Jenkins A; Virella G; Lopes-Virella MF;
Atherosclerosis; 2013 Dec; 231(2):315-22. PubMed ID: 24267245
[TBL] [Abstract][Full Text] [Related]
5. High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.
Lopes-Virella MF; Carter RE; Baker NL; Lachin J; Virella G;
Nephrol Dial Transplant; 2012 Apr; 27(4):1416-23. PubMed ID: 21856760
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus.
Lopes-Virella MF; Virella G; Orchard TJ; Koskinen S; Evans RW; Becker DJ; Forrest KY
Clin Immunol; 1999 Feb; 90(2):165-72. PubMed ID: 10080827
[TBL] [Abstract][Full Text] [Related]
7. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lyons TJ; Jenkins AJ; Virella G;
Diabetes Care; 2012 Jun; 35(6):1333-40. PubMed ID: 22511260
[TBL] [Abstract][Full Text] [Related]
8. High levels of AGE-LDL, and of IgG antibodies reacting with MDA-lysine epitopes expressed by oxLDL and MDA-LDL in circulating immune complexes predict macroalbuminuria in patients with type 2 diabetes.
Lopes-Virella MF; Hunt KJ; Baker NL; Virella G;
J Diabetes Complications; 2016; 30(4):693-9. PubMed ID: 26861948
[TBL] [Abstract][Full Text] [Related]
9. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.
Lopes-Virella MF; Baker NL; Hunt KJ; Lachin J; Nathan D; Virella G;
Atherosclerosis; 2011 Feb; 214(2):462-7. PubMed ID: 21156319
[TBL] [Abstract][Full Text] [Related]
10. Modified LDL Immune Complexes and Cardiovascular Disease.
Lopes-Virella MF; Virella G
Curr Med Chem; 2019; 26(9):1680-1692. PubMed ID: 29792135
[TBL] [Abstract][Full Text] [Related]
11. OxPL/apoB, lipoprotein(a) and OxLDL biomarkers and cardiovascular disease in chronic hemodialysis patients.
Bossola M; Tazza L; Luciani G; Tortorelli A; Tsimikas S
J Nephrol; 2011; 24(5):581-8. PubMed ID: 21404224
[TBL] [Abstract][Full Text] [Related]
12. Soluble LDL-immune complexes in type 2 diabetes and vascular disease.
Turk Z; Sesto M; Skodlar J; Ferencak G; Turk N; Stavljenić-Rukavina A
Horm Metab Res; 2002 Apr; 34(4):196-201. PubMed ID: 11987029
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study.
Orchard TJ; Virella G; Forrest KY; Evans RW; Becker DJ; Lopes-Virella MF
Diabetes; 1999 Jul; 48(7):1454-8. PubMed ID: 10389853
[TBL] [Abstract][Full Text] [Related]
14. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL.
Virella G; Atchley D; Koskinen S; Zheng D; Lopes-Virella MF;
Clin Immunol; 2002 Oct; 105(1):81-92. PubMed ID: 12483997
[TBL] [Abstract][Full Text] [Related]
15. LDL cholesterol is not a good marker of cardiovascular risk in Type 1 diabetes.
Hero C; Svensson AM; Gidlund P; Gudbjörnsdottir S; Eliasson B; Eeg-Olofsson K
Diabet Med; 2016 Mar; 33(3):316-23. PubMed ID: 26498834
[TBL] [Abstract][Full Text] [Related]
16. Association of apolipoprotein A phenotypes and oxidized low-density lipoprotein immune complexes in children.
Islam S; Gutin B; Treiber F; Hobbs G; Kamboh I; Lopes-Virella M
Arch Pediatr Adolesc Med; 1999 Jan; 153(1):57-62. PubMed ID: 9895000
[TBL] [Abstract][Full Text] [Related]
17. Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention.
Lee EY; Yang Y; Kim HS; Cho JH; Yoon KH; Chung WS; Lee SH; Chang K
Atherosclerosis; 2018 Dec; 279():1-9. PubMed ID: 30359786
[TBL] [Abstract][Full Text] [Related]
18. Immune complexes containing malondialdehyde (MDA) LDL induce apoptosis in human macrophages.
Virella G; Wilson K; Elkes J; Hammad SM; Rajab HA; Li Y; Chassereau C; Huang Y; Lopes-Virella M
Clin Immunol; 2018 Feb; 187():1-9. PubMed ID: 28689783
[TBL] [Abstract][Full Text] [Related]
19. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies.
Virella G; Thorpe SR; Alderson NL; Derrick MB; Chassereau C; Rhett JM; Lopes-Virella MF
J Lipid Res; 2004 Oct; 45(10):1859-67. PubMed ID: 15258197
[TBL] [Abstract][Full Text] [Related]
20. oxLDL - the molecule linking hypercoagulability with the presence of cardiovascular disease in hemodialyzed uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2014 Sep; 134(3):711-6. PubMed ID: 25065558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
